SEC Form 4 · accession 0001193125-26-312397
Sagimet Biosciences Inc. · SGMT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Happel
Officer — President & CEO · Director
Period of report
Jul 20, 2026
Accepted (ET)
Jul 22, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001400118
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Series A Common StockF2 | Jul 20, 2026 | S | 64,051 | $7.7605 | D | 741,570 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.76 to $7.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.